R&D News | pharmaphorum

News

Gilead NASH drug fails late stage trial

Gilead's top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a phase 3 trial.

News

Scotland says no to Yescarta, but backs Kymriah

Scotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types of lymphoma, but gave a green light to Novar

News

Artificial neuron in concept of artificial intelligence. Wall-shaped binary codes make transmission lines of pulses and/or information in an analogy to a microchip. Neural network and data transmission.

UCB joins with UK charity to research new epilepsy drugs

Belgium’s UCB has joined forces with the UK’s Epilepsy Society in a collaboration aimed at finding treatments for people who have the disease, but do not respond to current treatments.

News

Pharma companies clear the R&D decks in Q4

The fourth-quarter results season has already seen a host of unwanted projects cleared from pharma companies' pipelines as they tighten their focus on the projects with the most chance of a

News

Pills spilling out of a prescription bottle on 100 dollar paper currency

Alector kicks off biotech IPOs after US government shutdown

The 35-day US government shutdown has not just played havoc at government-run agencies – it has had a knock-on effect on the stock market because of cutbacks at the Securities and Exchange

News